ZIOPHARM Announces Three Presentations at the 2017 Annual Meeting of the Society for Neuro-Oncology

On October 12, 2017 ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on developing gene and cell-based immunotherapies for cancer, reported that three abstracts highlighting data from the Company’s Ad-RTS-hIL-12 + veledimex program have been accepted for presentation at the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO). The meeting will be held Nov (Press release, Ziopharm, OCT 12, 2017, View Source [SID1234520884]). 16 – 19 in San Francisco. Additional information will be available from the Society when all abstracts are released from embargo on Nov. 6.

Details for the SNO presentations with discussion are as follows:

E-Talk: A Phase 1 study of Ad-RTS-hIL-12 + veledimex in adult recurrent glioblastoma
Presenter: E. Antonio Chiocca, M.D., Ph.D.
Session Title: Adult Therapeutics
Date and Time: Saturday, Nov. 18, 5:32 — 5:36 p.m. PST
Abstract Code: ATIM-26

Oral Presentation: Controlled expression of IL-12 improves survival in glioma by activating the immune response in mice and humans
Presenter: John A. Barrett, Ph.D.
Session Title: Immunology — Preclinical and Clinical I
Date and Time: Sunday, Nov. 19, 9:15 – 9:20 a.m. PST
Abstract Code: IMMU-34

Oral Presentation: Controlled local expression of IL-12 as gene therapy concomitant with systemic chemotherapy improves survival in glioma
Presenter: John A. Barrett, Ph.D.
Session Title: Immunology — Preclinical and Clinical I
Date and Time: Sunday, Nov. 19, 10 – 10:05 a.m. PST
Abstract Code: IMMU-33

About Ad-RTS-hIL-12 plus Veledimex

ZIOPHARM is advancing Ad-RTS-hIL-12 plus veledimex as a gene therapy for glioblastoma. Ad-RTS-hIL-12 is an adenoviral vector administered via a single injection into the tumor and engineered to express hIL-12, a powerful cytokine that has demonstrated the potential to stimulate a targeted, anti-tumor immune response. The expression of hIL-12 is controlled and modulated with the RheoSwitch Therapeutic System (RTS) by the small molecule veledimex, an activator ligand which has been shown to cross the blood brain barrier. ZIOPHARM anticipates initiation of a pivotal trial for Ad-RTS-hIL-12 plus veledimex for the treatment of rGBM by the end of 2017. The Company also has initiated a Phase 1 study to evaluate the stereotactic administration of Ad-RTS-hIL-12 plus veledimex in adult patients with rGBM, and plans to initiate enrollment of adult patients with rGBM who will receive a single dose of Ad-RTS-hIL-12 plus veledimex in combination with a checkpoint inhibitor targeting programmed cell death protein 1 (PD-1) by the end of the year.